Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Ozempic, was originally developed to manage type 2 diabetes but has demonstrated remarkable weight loss effects in clinical trials. Patients taking semaglutide experience appetite suppression and improved metabolic function, making it one of the most studied medications for simultaneous diabetes and weight management. Understanding how this medication works can help you decide if it fits your health goals.

How Semaglutide Works for Diabetics and Weight Loss

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a natural hormone that regulates blood sugar and appetite signals in the brain. When semaglutide activates GLP-1 receptors, it slows how quickly food leaves your stomach, sending satiety signals to your hypothalamus. This dual action helps diabetics eat less while maintaining better glucose stability throughout the day.

The medication also improves how your pancreas produces insulin, especially when you eat carbohydrates. For type 2 diabetics, this means better postprandial glucose control without the crash-and-hunger cycles common with insulin alone. The weight loss effect emerges gradually as appetite suppression compounds over weeks of consistent use.

Clinical Evidence: Weight Loss Outcomes in Type 2 Diabetes Studies

The SUSTAIN trials demonstrated that semaglutide at 1.0 mg weekly produced an average weight loss of 6.5 kg (14 lbs) in type 2 diabetics over 30 weeks, independent of diet changes alone. When combined with structured lifestyle interventions, weight loss reached 10-15% of baseline body weight, with many patients maintaining these results long-term. Hemoglobin A1c improvements of 1.5-1.8% occurred simultaneously, showing that weight loss and diabetes control reinforced each other.

Importantly, semaglutide-induced weight loss predominantly targets visceral fat—the dangerous fat surrounding organs that drives insulin resistance. This preferential fat loss improves cardiovascular risk factors beyond what diet or exercise typically achieve alone. Studies tracking diabetic patients for two years show sustained benefits when the medication is continued, with weight regain occurring gradually after discontinuation.

Semaglutide vs. Other Diabetes Medications for Weight Management

Traditional diabetes drugs like metformin and sulfonylureas either cause weight gain or produce neutral effects on body weight. Insulin therapy often triggers weight gain due to improved glucose uptake by fat cells and increased hunger signals. Semaglutide distinguishes itself by actively reducing appetite while lowering blood sugar, addressing both conditions simultaneously in a way older medications cannot.

SGLT2 inhibitors produce modest weight loss (2-3 kg) through urinary glucose excretion, while GLP-1 receptor agonists like semaglutide create sustained weight reduction through central nervous system satiety pathways. For diabetics prioritizing weight management alongside glucose control, semaglutide offers superior outcomes compared to monotherapy with alternative agents. Combination therapy with metformin remains effective and may enhance results.

Starting Semaglutide: Dosing, Timeline, and What to Expect

Semaglutide treatment begins at a low dose (0.25 mg weekly) to minimize gastrointestinal side effects, then titrates upward every four weeks until reaching your therapeutic dose. Most patients feel appetite suppression within 2-3 weeks, though weight loss typically becomes measurable by week 6-8. The injection is administered once weekly, on the same day each week, using a pen that stores the medication in your refrigerator.

Expect mild nausea during the first 2-3 weeks as your body adjusts—eating smaller, protein-rich meals helps manage this transition. Constipation or loose stools may occur temporarily as stomach emptying slows. Energy levels improve as blood sugar stabilizes, and many diabetics report reduced cravings for refined carbohydrates and sugary foods within the first month of treatment.

PlexusDx Compounded Semaglutide: Accessibility and Personalized Treatment

PlexusDx provides compounded semaglutide injection from licensed 503A compounding pharmacies to patients across all 50 states without requiring insurance or membership fees. Pricing starts at $149 per month with flat-rate commitment tiers—your dose may increase over time, but your price remains stable. HSA and FSA accounts cover treatment, and no prior authorization delays treatment initiation.

PlexusDx's Precision Peptide Genetic Test maps 14 metabolic pathways and analyzes 49 peptides to identify genetic variants affecting GLP-1 receptor sensitivity and appetite regulation. Testing examines key variants like GLP1R rs6923761 and GIPR rs1800437 to predict individual response patterns, helping clinicians optimize your semaglutide dosing strategy. This personalized approach means your medication regimen aligns with your unique genetic predispositions rather than following a one-size-fits-all protocol.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can people without diabetes use semaglutide for weight loss alone?

Yes. While semaglutide was developed for type 2 diabetes, the FDA approved higher-dose formulations specifically for chronic weight management in non-diabetic individuals. The appetite suppression mechanism works independently of diabetes status, though blood sugar benefits occur only in people with dysglycemia. PlexusDx offers semaglutide to patients with and without diabetes, depending on clinical assessment and health goals.

How much weight do most diabetics lose on semaglutide?

Clinical trials show average weight loss of 10-15% of baseline body weight over one year in type 2 diabetics using semaglutide at standard doses. Individual results vary significantly—some patients lose 5-8%, while others achieve 20%+ reductions, influenced by genetics, adherence, and lifestyle factors. PlexusDx's Precision Peptide Genetic Test identifies genetic predictors of medication response to help set realistic expectations for your outcomes.

Does semaglutide from PlexusDx cost more or less than brand-name Ozempic?

PlexusDx compounded semaglutide injection starts at $149 monthly—significantly less than brand-name Ozempic, which costs $900-1,200 monthly without insurance. Pricing remains flat regardless of dose escalation, and no insurance is required. Treatment is HSA/FSA eligible, making it accessible to most patients seeking affordable, high-quality diabetes and weight loss therapy.

What are the most common side effects of semaglutide?

Nausea, constipation, and reduced appetite are most common during the first 2-4 weeks but typically resolve as your body adapts. Vomiting, diarrhea, or headaches occur in a smaller percentage of patients. Serious side effects like pancreatitis are rare, but you should discontinue treatment and seek medical attention if you experience severe abdominal pain, persistent vomiting, or signs of thyroid disease.

How does PlexusDx's Precision Peptide Genetic Test improve semaglutide treatment?

The test identifies genetic variants in GLP1R, GIPR, FTO, and MC4R pathways that influence how effectively your body responds to semaglutide. Patients with favorable GLP1R variants typically achieve stronger appetite suppression at lower doses, while those with less-responsive variants may require higher doses or combination therapy. This genetic insight helps PlexusDx clinicians personalize your dosing strategy from the start, maximizing weight loss and diabetes control while minimizing unnecessary dose escalation.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves